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Abstract
Background: The pandemic potential of avian influenza A/H5N1 should not be overlooked, and the continued
development of vaccines against these highly pathogenic viruses is a public health priority.
Methods: This open-label extension booster study followed a Phase III study of 1206 adults who had received two
3.75 μg doses of primary AS03A-adjuvanted or non-adjuvanted H5N1 split-virus vaccine (A/Vietnam/1194/2004; clade 1)
(NCT00449670). The aim of the extension study was to evaluate different timings for heterologous AS03A-adjuvanted
booster vaccination (A/Indonesia/5/2005; clade 2.1) given at Month 6, 12, or 36 post-primary vaccination. Immunogenicity
was assessed 21 days after each booster vaccination and the persistence of immune responses against the primary
vaccine strain (A/Vietnam) and the booster strain (A/Indonesia) was evaluated up to Month 48 post-primary vaccination.
Reactogenicity and safety were also assessed.
Results: After booster vaccination given at Month 6, HI antibody responses to primary vaccine, and booster vaccine
strains were markedly higher with one dose of AS03A-H5N1 booster vaccine in the AS03A-adjuvanted primary vaccine
group compared with two doses of booster vaccine in the non-adjuvanted primary vaccine group. HI antibody responses
were robust against the primary and booster vaccine strains 21 days after boosting at Month 12 or 36. At Month 48, in
subjects boosted at Month 6, 12, or 36, HI antibody titers of ≥1:40 against the booster strain persisted in 39.2%, 61.2%,
and 95.6% of subjects, respectively. Neutralizing antibody responses and cell-mediated immune responses also showed
that AS03A-H5N1 heterologous booster vaccination elicited robust immune responses within 21 days of boosting at
Month 6, 12, or 36 post-primary vaccination. The booster vaccine was well tolerated, and no safety concerns were raised.
Conclusions: In Asian adults primed with two doses of AS03A-adjuvanted H5N1 pandemic influenza vaccine, strong
cross-clade anamnestic antibody responses were observed after one dose of AS03A-H5N1 heterologous booster vaccine
given at Month 6, 12, or 36 after priming, suggesting that AS03A-adjuvanted H5N1 vaccines may provide highly flexible
prime–boost schedules. Although immunogenicity decreased with time, vaccinated populations could potentially be
protected for up to three years after vaccination, which is likely to far exceed the peak of the a pandemic.
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Background
The first human case of avian-origin influenza A/H5N1
infection emerged in Hong Kong in 1997, and by July 2013,
the World Health Organization (WHO) had reported over
600 cases, of which more than half were lethal [1]. The ma-
jority of cases occur in people in close contact with poultry,
and although H5N1 infections do not appear to transmit
efficiently between humans, the pandemic potential of these
viruses should not be overlooked. Indeed, the unpredict-
able nature of influenza viruses was recently highlighted
by reports of human cases of a novel reassortant avian-
origin influenza A/H7N9 strain in China [2].
The development of vaccines against potentially dan-
gerous avian-origin influenza infections remains a public
health priority, and based on circulating viruses, the WHO
* Correspondence: paul.gillard@gsk.com
1GlaxoSmithKline Vaccines, Wavre, Belgium
Full list of author information is available at the end of the article
© 2014 Gillard et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Gillard et al. BMC Infectious Diseases 2014, 14:142
http://www.biomedcentral.com/1471-2334/14/142
recommends vaccines against H5N1 should include clade
1 or clade 2 strains [3]. However, it currently takes about
four to six months to produce an inactivated influenza vac-
cine, and the capacity of the manufacturing infrastructure
is limited, meaning that mitigating the spread of infection
until a vaccine becomes available and then supplying
enough vaccine to meet worldwide demand are major chal-
lenges. The formulation of H5N1 influenza vaccine with
the oil-in-water, tocopherol-based Adjuvant System, AS03,
may help address these challenges.
In adults, AS03A-adjuvanted H5N1 (A/Vietnam/1194/
2004) vaccine was shown to be significantly more immuno-
genic than non-adjuvanted vaccine, and two doses of adju-
vanted vaccine containing 3.75 μg of hemagglutinin antigen
(HA) fulfilled licensure criteria for vaccine immunogenicity
[4]. In addition to responses against the vaccine strain
(clade 1), AS03A-adjuvanted H5N1 vaccine provided strong
cross-reactivity to clade 1, 2.1, 2.2, and 2.3 drifted strains
[5]. Cross-reactive immunogenicity not only has the poten-
tial to provide protection against drift variants, but also of-
fers the opportunity for flexible priming strategies. For
example, a pre-pandemic strategy involves stockpiling vac-
cine matched to prevalent avian-origin H5N1 viruses based
on global surveillance, to be deployed during a pandemic
alert or at the start of the pandemic, which can be followed
by a booster dose of vaccine matched to the actual emer-
ging strain given when batches become available [6,7].
Previous studies of AS03A-adjuvanted H5N1 influenza
vaccines in adults were performed in populations in Europe
and North America, and included schedules with booster
doses 6 or 12 months post-primary [4,8-12]. More recently,
a large Phase III, lot production consistency study was
conducted in adults in Taiwan, Thailand, Singapore, and
Hong Kong, and confirmed that two doses of AS03A-
adjuvanted H5N1 vaccine (A/Vietnam/1194/2004; clade 1)
elicited robust hemagglutinin-inhibition (HI) and neutraliz-
ing antibody responses, which were markedly higher than
those observed with two doses of non-adjuvanted H5N1
vaccine [13]. Here we describe the staggered booster ex-
tension phase of the study, in which subjects in the
AS03A-adjuvanted H5N1 primary group received one
dose of heterologous booster vaccine (A/Indonesia/5/
2005; clade 2.1) at either Month 6, 12, or 36 post-primary
vaccination. Subjects in the initial non-adjuvanted H5N1
primary group received two doses of AS03A-adjuvanted
heterologous H5N1 booster vaccine at Month 6. The
aims were to assess the immunogenicity, including cross-




This Phase III open-label randomized extension study of
adults aged 18 to 60 years evaluated the immunogenicity
and safety of AS03A-adjuvanted H5N1 pandemic vaccine.
In the initial study, subjects received two doses given
21 days apart of primary AS03A-adjuvanted H5N1 pan-
demic vaccine or non-adjuvanted H5N1 vaccine in the
control group (both A/Vietnam/1194/2004; clade 1). Data
regarding the HI antibody responses to AS03A-H5N1 and
non-adjuvanted-H5N1 primary vaccine have been previ-
ously published, including the primary endpoint of the
lot-to-lot consistency of four AS03A-H5N1 primary vac-
cine lots, and immunogenicity against the vaccine and
drifted strains [13].
The aim of this extension study was to assess the immune
responses to heterologous booster vaccine (A/Indonesia/5/
2005; clade 2.1) given at different time-points post-primary
vaccination. Single doses of heterologous booster vaccine
were administered to subjects in the AS03A-adjuvanted
H5N1 primary vaccine group at either Month 6, 12, or 36
post-priming; immunogenicity against the primary vaccine
strain (A/Vietnam) and the booster strain (A/Indonesia)
were assessed after each booster vaccination, and the per-
sistence of immune responses were assessed in all subjects
up to Month 48 post-priming. Given their lower responses
to the primary vaccination shown in the initial study, all
subjects in the non-adjuvanted H5N1 primary vaccine
group received two doses of booster vaccine given 21 days
apart at Month 6 post-priming, and immunogenicity was
assessed after each booster dose.
In the extension study, the following assessments were
performed: In the AS03A-adjuvanted H5N1 primary vac-
cine group, HI, neutralizing, and cell-mediated immunity
antibody responses against A/Vietnam and A/Indonesia
were assessed 21 days after booster vaccine given at Month
6, 12 or 36 post-priming, and immunogenicity persistence
was evaluated at Month 12, 18, 24, 30, 36, 42, and 48 post-
priming, depending upon the timing of booster vaccin-
ation; in the non-adjuvanted-H5N1 primary vaccine group,
HI antibody responses were assessed 21 days after each
booster dose given at given at Month 6, and cell-mediated
immunity antibody responses were assessed 21 days after
each booster dose and at Month 12 post-priming; Reacto-
genicity was assessed for 7 days after each booster vaccin-
ation. Unsolicited adverse events (AEs) were assessed for
30 days after each booster vaccination, and serious adverse
events (SAEs) were assessed throughout.
Subjects and setting
This study was conducted in Taiwan, Thailand, Singapore,
and Hong Kong. Subjects were eligible for inclusion if they
were healthy and able to comply with the booster proto-
col; women of child-bearing potential had to practice ad-
equate contraception for 30 days before each vaccination
and for two months after vaccination. Exclusion criteria
included: the receipt of any licensed inactivated vaccines
within 2 weeks or live vaccines 4 weeks before study
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vaccines; previous receipt of AS03A-adjuvanted vaccine
(exclusion criterion for initial study); previous proven
contact with H5N1 wild type virus; use of immuno-
suppressants (for >14 days) within 6 months of study
vaccines; allergy to vaccine components; pregnancy or
breast-feeding; clinically significant chronic illness or
acute illness at enrollment.
All participants provided written informed consent. The
study protocol was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority
Hong Kong West Cluster, SingHealth Centralised Institu-
tional Review Boards, Research Ethics Committee of Taipei
Veterans General Hospital, and Siriraj Institutional Review
Board. The study was conducted in accordance with Good
Clinical Practice and the Declaration of Helsinki. The trials
for which data are reported here are registered at Clinical-
Trials.gov: NCT00449670 and NCT00652743. The study
protocols may be found at: http://www.gsk-clinicalstudy
register.com/ (study IDs 109630 and 111443).
Vaccines and vaccination
The H5N1 inactivated, split-virion recombinant influenza
vaccines were manufactured by GlaxoSmithKline (GSK)
Vaccines (Rixensart, Belgium). The primary vaccines
contained 3.75 μg HA of A/Vietnam/1194/2004, formu-
lated with an oil-in-water based emulsion Adjuvant System
(AS03) or as non-adjuvanted H5N1 vaccine. AS03A con-
tained DL-α-tocopherol (11.86 mg), squalene (10.69 mg),
polysorbate (4.86 mg), and thimerosal (5 μg). The booster
vaccine contained 3.75 μg HA of A/Indonesia/05/2005
formulated with AS03A. All vaccines were administered
as a 0.5 mL dose in the deltoid muscle of the non-
dominant arm.
Subjects from the initial study were invited to enter
the extension phase. In the initial study, 945 and 245
subjects, respectively, received AS03A-H5N1 and non-
adjuvanted H5N1 primary vaccine. All subjects in the
non-adjuvanted H5N1 primary vaccine group who en-
tered the extension study were allocated to receive two
doses of AS03A-heterologous booster vaccine at Month
6. A total of 265 subjects from the AS03A-H5N1 primary
vaccine group were randomly selected to receive one
dose of AS03A-heterologous booster vaccine at Month 6;
the remaining 578 subjects from the AS03A-H5N1 pri-
mary vaccine group who accepted participation in the
extension trial were randomized 30%:35%:35% to receive
one dose of booster vaccine at Month 12, 24, or 36. Al-
location to booster group was performed by the study
sponsor. Vaccination at Month 24 was put on hold due
to a potential safety concern that was raised during a
pooled analysis across the development programme, but
which was not specifically related to this trial. The con-
cern was subsequently lifted, and following a protocol
amendment, subjects who were originally scheduled to
receive booster vaccination at Month 24 instead re-
ceived the booster dose at Month 36.
Immunogenicity assessments
Humoral immune responses
All serological testing was performed in a central GSK
Vaccines laboratory or an external laboratory using stan-
dardized, validated procedures. Blood samples were taken
on Day 0, and on Days 21 and 42 (to assess priming
vaccine responses), and at Month 6, Month 6 + 21 days
and +42 days, at Month 12, Month 12 + 21 days, and
Month 36 and Month 36 + 21 day (to assess booster
vaccine responses), and at Months 18, 24, 30, 42, and 48
(to assess immune response persistence depending upon
timing of booster dose). HI assays were performed using
an established HI method, modified for horse rather than
avian erythrocytes [14-17].
HI antibody parameters were geometric mean titers
(GMT), seroprotection rates (SPR; percentage of sub-
jects with titers ≥1:40 following vaccination), and sero-
conversion rates (SCR; percentage of subjects achieving
an increase in titer from <1:10 pre-vaccination to ≥1:40,
or at least a 4-fold post-vaccination increase in titer from
a pre-vaccination titer ≥1:10). SCRs after booster vaccin-
ation (booster SCR) were based on increases in HI anti-
body titers from the pre-booster titer measured at the
booster time-point. Subjects with a titer of ≥1:10 were
considered to be seropositive.
Virus neutralization was determined using a micro-
neutralization assay on heat-inactivated sera as described
previously [14,16]. A standardized amount of virus was
incubated with serial dilutions of serum, and after fur-
ther incubation with Madin-Darby Canine Kidney cells,
virus replication was visualized by hemagglutination of
chicken erythrocytes. The neutralization titer of a serum
was calculated by the method of Reed and Muench [18].
Neutralizing antibody parameters measured were GMT,
seropositivity rate (percentage of subjects with titer ≥1:28),
and neutralizing booster seroconversion rate (neutralizing
booster SCR; percentage of subjects with pre-booster
titer <1:28 and post-vaccination titer of ≥1:56, or pre-
booster titer ≥1:28 and ≥4-fold post-vaccination). The
assay cut-off titer was 1:28.
Cell-mediated immune responses
Cell-mediated immune (CMI) responses were assessed
21 days after each dose of primary and booster vaccine and
at each time-point up to Month 48. Intracellular cytokine
staining was used to assess CMI responses, using an adap-
tation of previously described methods [19-21]. Briefly,
white blood cells were obtained from undiluted whole
blood samples and re-stimulated in vitro with A/Vietnam/
1194/2004 H5N1 split antigen in the presence of co-
stimulatory CD28 and CD49d antibodies, and Brefeldin A.
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Cells were incubated with fluorescence-conjugated anti-
bodies to surface CD4 and CD8 markers, and Th1-specific
activation markers, CD40L, IL-2, TNF-α and IFN-γ. Flow
cytometric acquisition was performed on a BD LSR II flow
cytometer and analyzed using BD Diva software (BD Bio-
sciences). Results were expressed as the frequency of CD4+
and CD8+ T-cells expressing two cytokines (doubles) or
each cytokine.
Reactogenicity and safety
Reactogenicity (solicited AEs) was assessed for 7 days after
each vaccination. Subjects were given diary cards to rec-
ord the occurrence and severity of injection site AEs (pain,
redness, swelling, ecchymosis, induration), and general
AEs (arthralgia, fatigue, fever, headache, myalgia). All soli-
cited injection site AEs were considered to be vaccine-
related, and investigators provided causality assessments
for solicited general events.
Unsolicited AEs were assessed for 30 days after each
after each vaccination, and SAEs were assessed through-
out the extension phase. All AEs were coded by pre-
ferred term and primary system organ class using the
Medical Dictionary for Regulatory Activities (MedDRA).
Investigators provided causality assessments for unsoli-
cited AEs.
Statistical analyses
The sample sizes for the boosting cohorts were based on
the assumption that at least 211 subjects would receive a
booster vaccination, and if the true HI SCR observed after
any booster vaccination is 60%, the probability of observ-
ing a 95% confidence interval (CI) lower limit of ≥40% is
greater than 99%.
Humoral immune responses at each specified time-
point were described with a 95% CI. Analyses of immuno-
genicity were based on the per-protocol immunogenicity
cohort, including subjects who were vaccinated and for
whom data were available for the outcome measure at a
given time-point, without fulfilling elimination criteria
(per-protocol immunogenicity cohort).
CMI responses were expressed as CD4+ or CD8+ T-cells
per million T-cells. CMI responses were assessed in a sub-
set of subjects in Taiwan (cell-mediated immunity cohort).
The incidence of reactogenicity and safety events was
tabulated with a 95% CI. Reactogenicity and safety ana-
lyses were performed on the total vaccinated cohort in-
cluding subjects who received ≥1 dose of vaccine, and
for whom any safety data were available.
Results
A total of 1206 subjects received primary vaccine in the ini-
tial primary vaccination study (Figure 1). In the extension
study, 265 and 236 subjects from the AS03A-H5N1 and
non-adjuvanted H5N1 primary vaccine groups, respectively,
were allocated to receive booster vaccination at Month 6
(Figure 1; Table 1). The median age and standard deviations
for each parameter across cohorts suggest that the groups
were balanced for demographic characteristics. The mean
age (range) of subjects in the per-protocol immunogenicity
cohort who were boosted at Month 6 was 33.3 years (19–
58 years). A total of 188 subjects received booster vaccin-
ation at Month 12 (per-protocol immunogenicity cohort),
and the mean age (range) of these subjects was 35.4 years
(21–59 years). A total of 387 subjects received booster vac-
cination at Month 36 (per-protocol immunogenicity co-
hort); the mean age (range) of these subjects was 38.0 years
(21–62 years). Across the study groups, a limited set of 39
subjects total (17 female, 22 male) were initially enrolled in
the CMI cohort in Taiwan only; the mean age (range) of
subjects was 31.0 years (23–50 years). Of these, 24 subjects
had available results at the final Month 48 visit.
In the initial study, the first subject was enrolled in
March 2007 and the last study contact was in July
2007, and in the extension study, the first subject was
enrolled in September 2007 and the final visit was in
June 2011.
Humoral immunogenicity
HI antibody responses to heterologous booster vaccination
at Month 6
HI GMTs against primary vaccine and booster vaccine
strains after the Month 6 heterologous booster vaccination
are shown in Figure 2. The GMTs after one dose of heter-
ologous booster in the AS03A-H5N1 primary group were
397.4 and 321.3 against the primary and booster strains, re-
spectively, and GMTs after two doses of booster vaccine in
the non-adjuvanted H5N1 primary group were 76.3 and
96.3 against the primary and booster strains, respectively
(Figure 2).
In subjects who received the AS03A-H5N1 primary
vaccine, SCRs were 96.1% and 94.9% against the primary
and booster vaccine strains, respectively, 21 days after
the Month 6 booster. The booster SCRs (using Month 6
pre-booster titer as the pre-vaccination titer), against the
primary and booster vaccine strains were 91.0% and 94.1%,
respectively (Table 2). In subjects who received non-
adjuvanted H5N1 primary vaccine, 21 days after the second
dose of AS03A-heterologous booster at Month 6, booster
SCRs were 75.9% and 82.9% against the primary and
booster strains, respectively. SPRs against the primary and
booster strains at Month 6 in the AS03A-H5N1 primary
vaccine group are shown in Figure 3.
The 95% CIs for the post-booster immunogenicity pa-
rameters do not overlap and are widely separated be-
tween the AS03A-H5N1 and the non-adjuvanted H5N1
primary vaccine groups. This suggests that AS03A-H5N1
primary vaccine followed by one dose of booster vaccine
provides significantly higher HI antibody responses than
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non-adjuvanted H5N1 primary vaccine followed by two
doses of booster vaccine.
HI antibody responses to heterologous booster vaccination
at Month 12 and Month 36
SPRs against the primary and booster strains in subjects
boosted at Month 12 or 36 are shown in Figure 3.
In subjects boosted at Month 12, booster SCRs 21 days
after vaccination (using Month 12 pre-booster as the
pre-vaccination titer) were 95.6% and 93.9%, against the
primary and booster strains, respectively.
In subjects who were not boosted at Month 6 or 12,
16.3% and 7.8% of subjects were seroprotected (titer ≥1:40)
for the primary and booster strain, respectively, before the
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Figure 1 Subject flow diagram. †Initial study; TVC, total vaccinated cohort; CMI, cell-mediated immunity; NA H5N1, non-adjuvanted primary
vaccine group’; AS03A-H5N1, adjuvanted primary vaccine group.
Table 1 Demographic characteristics in the per-protocol immunogenicity cohort
Primary vaccine group
AS03A-H5N1 Non-adjuvanted-H5N1
N = 954† N = 245†
Heterologous booster group per-protocol immunogenicity cohort
Month 6 Month 12 Month 36 Month 6
N = 256 N = 186 N = 387 N = 229
Mean age, years 33.3 35.4 38.0 33.5
(SD, range) (10.16; 19–58) (9.24; 21–59) (9.74; 21–62) (9.17; 19–58)
Male, n (%) 117 (45.7) 89 (48.4) 201 (51.9) 115 (50.2)
Female, n (%) 139 (54.3) 95 (51.6) 186 (48.1) 114 (49.8)
Central/South Asian Heritage 1 (0.4) 2 (1.1) 3 (0.8) 5 (2.2)
East Asian Heritage 154 (60.2) 115 (62.5) 225 (58.1) 135 (59.0)
South East Asian heritage 101 (39.5) 66 (35.9) 159 (41.1) 88 (38.4)
Arabic/North African Heritage – – – 1 (0.4)
†Total vaccinated cohort in initial study; SD, standard deviation; N, number of subjects in group.
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H5N1 primary vaccine, 21 days after heterologous booster
vaccination given at Month 36, the SPR was 100% against
the primary and booster strains (Figure 3). Booster SCRs
(using Month 36 pre-booster as pre-vaccination titer) were
99.5% and 98.1% against the primary and booster strains,
respectively.
Persistence of HI antibody responses to heterologous
booster up to Month 48
GMTs and SPRs in the per-protocol persistence cohorts
are shown in Table 3 and Figure 3. In subjects who re-
ceived AS03A-H5N1 primary vaccine followed by booster
at Month 6, GMTs at Month 12 were 76.1 and 46.9
against the primary and booster strains, respectively. At
Month 18, 36, and 48, SPRs were 69.0%, 43.3%, and
45.4%, respectively, against the primary vaccine strain,
and 72.7%, 50.0%, and 39.2%, respectively, against the
booster strain.
In subjects who received a booster dose at Month 12,
SPRs at Month 18 were 89.6% and 91.8% against the pri-
mary vaccine and booster strains, respectively. HI antibody
responses persisted until the end of follow-up (a minimum
of 2 years); SPRs at Month 36 and 48 were 68.0% and
67.1%, respectively, against the primary vaccine strain, and
70.8% and 61.2%, respectively, against the booster strain.
In subjects who received a booster dose at Month 36,
HI antibody responses persisted at Month 48; SPRs at
Month 48 were 95.1% and 95.6% against the primary
vaccine strain and the booster strain, respectively.
Neutralizing antibody responses to heterologous booster
vaccination at Month 6, 12, and 36
Neutralizing antibody GMTs 21 days after one booster
dose in the AS03A-H5N1 primary group were 1660.1 and
2917.5 against the vaccine and booster strains, respectively,
and neutralizing GMTs after two doses of booster in the
non-adjuvanted H5N1 group were 447.1 and 1075.8 against
the vaccine and booster strains, respectively. The propor-
tion of subjects with neutralizing antibody titers ≥1:28 and
booster SCRs followed the same pattern as neutralizing
GMTs after boosting at Month 6 (Table 4). The booster
SCRs 21 days after one booster dose in the AS03A-H5N1
primary group were 74.2% and 88.9% against the vaccine
and booster strains, respectively, and after two doses
of booster vaccine in the non-adjuvanted H5N1 primary
group were 91.1% and 95.7%, respectively (Table 4).
Persistence of neutralizing antibody responses up to
Month 48
The persistence of neutralizing antibody responses up to
Month 48 after booster vaccination in subjects in the
AS03A-H5N1 primary group who were boosted at Month
6, 12, or 36 is shown in Table 4. The booster SCRs against
the primary vaccine strain at 21 days after booster vaccin-
ation were 74.2%, 86.0%, and 98.6%, in subjects boosted at
Month 6, 12, or 36, respectively, and against the booster
vaccine strain were 88.9%, 97.0%, and 100%, respectively.
At Month 48, the booster SCRs in subjects boosted at






























Figure 2 Hemagglutination-inhibition antibody Geometric Mean Titers after primary vaccination and heterologous booster vaccination
at Month 6 in the per-protocol immunogenicity cohort. †Pre-vaccination values; CI, confidence interval; GMT, geometric mean titer. Subjects
in the AS03-H5N1 primary vaccine group received one dose of heterologous booster at Month 6; Subjects in the non-adjuvanted-H5N1 primary
vaccine group received two doses of heterologous booster at Month 6, given 21 days apart.
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against the primary vaccine strain, and were 1.3%, 36.0%,
and 96.0%, respectively, against the booster vaccine strain
(Table 4).
Cell-mediated immunity
No baseline CMI values were available due to a problem
with the Day 0 sample shipment. At 21 days after pri-
mary vaccination, there was a substantial CD4+ T-cell
response in the AS03A-H5N1 group. After heterologous
booster vaccination at Month 6, there was a substantial
CD4+ T-cell response against the primary vaccine strain.
CD4+ T-cell responses persisted in both groups at Month
12 (Figure 4).
The CD4+ T-cell response in the AS03A-H5N1 group
boosted at Month 6, 12, and 36 with follow-up to Month
48 is shown in Additional file 1. At 21 days after each
booster vaccination, there was a substantial CD4+ T-cell
response against the primary and booster vaccine strains.
For example, 21 days after booster vaccine at Month 6,
12, and 36, median frequencies of CD40L-positive cells
responsive to the booster and primary vaccine strains
were 5292.0 and 6931.0, 9416.0 and 9587.0, and 5038.0
and 5296.0 per million CD4+ T-cells, respectively. Median
CD40L-positive cells at Month 48 in subjects boosted at
Month 6, 12, and 36 for the booster strain were 1496.0,
2013.5, and 2008.0 per million CD4+ T-cells, respectively.
There were no CD8+ T-cell responses observed in
either vaccine group at any time-point.
Reactogenicity
Solicited injection site adverse events
A summary of solicited injection site AEs after booster
vaccination is shown in Figure 5. In the AS03A-H5N1
group, after booster vaccination at Month 6, 12, and 36
overall, the rate of injection site AEs was 81.9% (217/
265), 84.6% (159/188), and 80.0% (312/390), respectively,
including 5.3% (14/265), 5.9% (11/188), and 4.4% (17/
390) Grade 3 events, respectively.
After booster vaccination, pain was the most frequent
injection site event, and Grade 3 pain was uncommon.




n/N; % (95% CI) n/N; % (95% CI)
Primary strain Booster strain Primary strain Booster strain
AS03A-H5N1 Day 0 – – 15/933; 1.6 1/933; 0.1
(0.9, 2.6) (0.0, 0.6)
Day 21 393/925; 42.5 24/925; 2.6 412/925; 44.5 27/925; 2.9
(39.3, 45.7) (1.7, 3.8) (41.3, 47.8) (1.9, 4.2)
Day 42 866/924; 93.7 464/924; 50.2 871/924; 94.3 464/924; 50.2
(92.0, 95.2) (46.9, 53.5) (92.6, 95.7) (46.9, 53.5)
Heterologous booster Month 6 – – 103/251; 41.0 9/251; 3.6
(34.9, 47.4) (1.7, 6.7)
Month 6 + 21 233/256; 91.0† 241/256; 94.1† 242/251; 96.4 238/251; 94.8
(86.8, 94.2) (90.5, 96.7) (93.3, 98.3) (91.3, 97.2)
Non-adjuvanted-H5N1 Day 0 – – 5/236; 2.1 0/236; 0.0
(0.7, 4.9) (0.0, 1.6)
Day 21 8/234; 3.4 0/234; 0.0 16/234; 6.8 0/234; 0.0
(1.5, 6.6) (0.0, 1.6) (4.0, 10.9) (0.0, 1.6)
Day 42 13/234; 5.6 1/234; 0.4 24/234; 10.3 1/234; 0.4
(3.0, 9.3) (0.0, 2.4) (6.7, 14.9) (0.0, 2.4)
Heterologous booster Month 6 – – 4/224; 1.8 0/224; 0.0
(0.5, 4.5) (0.0, 1.6)
Month 6 + 21 112/228; 49.1† 106/228; 46.5† 120/223; 53.8 105/223; 47.1
(42.5, 55.8) (39.9, 53.2) (47.0, 60.5) (40.4, 53.9)
Month 6 + 42 173/228; 75.9† 189/228; 82.9† 180/228; 78.9 189/228; 82.9
(69.8, 81.3) (77.4, 87.5) (73.1, 84.1) (77.4, 87.5)
CI, Confidence Interval; n/N, number of subjects fulfilling criteria for defined outcome/total number of subjects in group; SCR, seroconversion rates defined as
percentage of subjects achieving an increase in HI titers from <1:10 to ≥1:40 or at least a 4-fold post-vaccination increase in HI titer from a pre-vaccination titer ≥1:10;
†Booster SCR was SCR based on increases in HI antibody titers from pre-vaccination titers at Month 6; SPR, seroprotection rate defined as the percentage of subjects with
HI titers ≥1:40 following vaccination; primary vaccine strain, H5N1/A/Vietnam/1194/2004; booster strain H5N1/A/Indonesia/5/2005.
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After booster vaccination at Month 6, pain was the most
frequent solicited injection site AE in the AS03A-H5N1 pri-
mary group (80.8%; 214/265) and in the non-adjuvanted
H5N1 primary group (84.3%; 198/235). There were no re-
ports of Grade 3 pain at Month 6. After booster vaccination
at Month 12, injection site pain was the most frequent
solicited injection site AE (84.0%; 158/188) and Grade 3
pain was uncommon (5.9%; 11/188). After the Month
36 booster, pain was the most frequent solicited injection
site AE (79.3%; 306/380). There were no reports of Grade
3 pain at Month 36.
Solicited general adverse events
A summary of solicited general events after booster vac-
cination is shown in Figure 5. In the AS03A-H5N1 group,
after booster at Month 6, 12, and 36, the rate of general
events was 78.9% (209/265), 78.2% (147/188), and 76.9%
(300/390), respectively, including 10.9% (29/265), 10.6%
(20/188), and 6.9% (27/390), Grade 3 AEs overall.
After booster vaccination, myalgia and fatigue were the
most frequent general events, and Grade 3 general events
were uncommon. In the AS03A-H5N1 primary group, after
booster vaccination at Month 6, the most frequent soli-
cited general AEs were myalgia (63.8%; 169/265) and fa-
tigue (62.3%; 165/265). In the non-adjuvanted H5N1
primary group, after heterologous booster vaccinations at
Month 6, the most frequent solicited general AEs overall
by subject were myalgia (60.0%; 141/235) and fatigue
(51.5%; 121/235). After booster vaccination at Month 12,
the most frequent solicited general AEs were myalgia
(65.4%; 123/188) and fatigue (59.6%; 112/188). After the
Month 36 booster, myalgia (60.9%; 235/386) and fatigue
(56.0%; 216/386) were the most frequent general AEs.
Safety
Unsolicited AEs during the 30-day post-vaccination period
A summary of safety is shown in Table 5. During 30 days
after heterologous booster vaccination at Month 6 in the
AS03A-H5N1 primary vaccine group, there were 24.5%
(65/265) unsolicited AEs, and during the 30 day post-
vaccination periods after two doses of heterologous booster
vaccination in the non-adjuvanted H5N1 primary group,
there were 22.9% (54/236) unsolicited AEs. For 30 days






































































I Booster vaccine strain (A/Indonesia/5/2005)
Boosted at Month 6 
Boosted at Month 12 
Boosted at Month 36 
M48
M48
Figure 3 Persistence of hemagglutination-inhibition antibody seroprotection from Month 6 to 48 in subjects who received AS03A-H5N1
primary vaccine in the per-protocol immunogenicity cohort. CI, confidence interval; Seroprotection rates defined as the percentage of subjects
with post-vaccination HI titers ≥1:40.
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Table 3 Persistence of hemagglutination-inhibition antibody geometric mean titers with 95% CI in the per-protocol immunogenicity cohort
Month 6 6 + 21 days 12 12 + 21 days 18 24 30 36 36 + 21 days 42 48
Boosted at Month 6
Primary strain N = 256 N = 256 N = 228 – N = 216 N = 200 N = 200 N = 208 – N = 201 N = 194
19.1 397.4 76.1 43.7 32.2 27.5 24.3 20.1 22.9
(16.5, 22.5) (342.5, 461.0) (62.5, 92.7) (36.7, 52.0) (27.3, 37.9) (23.6, 32.2) (20.6, 28.6) (17.3, 23.5) (19.6, 26.9)
Booster strain N = 256 N = 256 N = 228 – N = 216 N = 200 N = 200 N = 208 – N = 201 N = 194
6.4 321.3 46.9 4.9 22.2 22.1 24.5 17.8 19.5
(6, 6.9) (274.3, 376.2) (38.3, 57.4) (45.6, 66.1) (18.8, 26.0) (18.8, 26.0) (20.6, 29.1) (15.2, 20.9) (16.6, 23.0)
Boosted at Month 12
Primary strain N = 665 – N = 178 N = 184 N = 182 N = 177 N = 177 N = 178 – N = 176 N = 170
18.5 11.8 649.7 145.2 68.5 53.0 51.2 39.0 41.8
(5, 5.1) (10.0, 14.0) (549.6, 768.1) (118.1, 178.6) (55.9, 83.9) (44.6, 63.1) (42.3, 62.0) (32.6, 46.6) (34.7, 50.4)
Booster strain N = 665 – N = 178 N = 184 N = 182 N = 177 N = 177 N = 178 – N = 176 N = 170
6.3 6.2 338 190.7 51.3 45.5 52.4 37 37.9
(6, 6.5) (5.7, 6.7) (280, 407.2) (154.3, 235.7) (44.6, 63.1) (37.2, 55.8) (42.3, 65.1) (30.3, 45.2) (30.9, 46.4)
Boosted at Month 36
Primary strain – – N = 365 – N = 429 N = 411 N = 413 N = 387 N = 379 N = 378 N = 367
11.3 10.2 10.8 10.7 10.5 653.1 225.4 165.1
(10.1, 12.6) (9.3, 11.3) (9.8, 11.8) (9.7, 11.7) (9.5, 11.6) (604.3–705.9) (205, 247.9) (149.8, 181.9)
Booster strain – – N = 364 – N = 429 N = 411 N = 413 N = 387 N = 379 N = 378 N = 367
6.2 9.6 6.0 6.3 7.0 877.5 263.5 171.3
(5.8, 6.7) (8.7, 10.6) (5.7, 6.3) (6.0, 6.6) (6.5, 7.6) (809.1, 951.6) (238.3, 291.3) (155.0, 189.3)
CI, confidence interval; N, number of subjects in group; Responses are based on per-protocol immunogenicity cohort before vaccination and at vaccination + 21 days; responses at time-points post-vaccination are




















Table 4 Neutralizing antibody-based immunogenicity with 95% CI in the per-protocol immunogenicity cohort
Month 6 6 + 21 days 12 12 + 21 24 36 36 + 21 48
Titre ≥1:28 n/N; % (95% CI) Booster at Month 6
Primary strain 162/163; 99.4 163/163; 100 75/75; 100 – 74/75; 98.7 71/75; 94.7 – 73/75; 97.3
(96.6, 100) (97.8, 100) (95.2, 100) (92.8, 100) (86.9, 98.5) (90.7, 99.7)
Booster strain 160/162; 98.8 162/162; 100 74/74; 100 – 70/74; 94.6 66/75; 88.0 – 67/75; 89.3
(95.6, 99.9) (97.7, 100) (95.1, 100) (86.7, 98.5) (78.4, 94.4) (80.1, 95.3)
Booster Month 12
Primary strain – – 162/164; 98.8 170/170; 100 75/75; 100 73/74; 98.6 – 74/75; 98.7
(95.7, 99.9) (97.9, 100) (95.2, 100) (92.7, 100) (92.8, 100)
Booster strain – – 135/164; 82.3 170/170; 100 72/75; 96.0 69/74; 93.2 – 73/75; 97.3
(75.6, 87.8) (97.9, 100) (88.8, 99.2) (84.9, 97.8) (90.7, 99.7)
Booster Month 36
Primary strain – – – – 58/75; 77.3 55/75; 73.3 74/74; 100 74/75; 98.7
(66.2, 86.2) (61.9, 82.9) (95.1, 100) (92.8, 100)
Booster strain – – – – 17/75; 22.7 19/75; 25.3 75/75; 100 74/75; 98.7
(13.8, 33.8) (16.0, 36.7) (95.2, 100) (92.8, 100)
Month 6 6 + 21 days 12 12 + 21 24 36 36 + 21 48
GMT value (95% CI) Booster at Month 6
Primary strain 169.9; 1566.3; 159.4; – 74.0; 62.0; – 71.4;
(152.3, 189.4) (1342.1, 1827.9) (128.1, 198.2) (62.5, 87.5) (52.1, 73.7) (61.8, 82.5)
Booster strain 179.7; 2702.0; 134.0; – 66.3; 55.4; – 54.5;
(161.8, 199.7) (2270.4, 3215.6) (107.4, 167.3) (54.5, 80.8) (45.5, 67.6) (45.8, 64.7)
Booster Month 12
Primary strain – – 204.1; 2734.9; 164.9; 121.1; – 117.4;
(179.9, 231.6) (2334.4, 3204.2) (125.7, 216.2) (91.7, 159.9) (92.7, 148.6)
Booster strain – – 58.5; 2363.2; 148.9; 106.9; – 103.4;
(50.8, 67.3) (2037.5, 2740.9) (111.8, 198.3) (81.6, 140.0) (79.5, 134.4)
Booster Month 36
Primary strain – – – – 33.3; 31.8; 1373.4; 429.0;
(28.8, 38.4) (27.3, 36.9) (1023.7, 1842.6) (322.2, 571.2)
Booster strain – – – – 16.7; 17.3; 1154.3; 320.4;




















Table 4 Neutralizing antibody-based immunogenicity with 95% CI in the per-protocol immunogenicity cohort (Continued)
Month 6 6 + 21 days 12 12 + 21 24 36 36 + 21 48
Booster SCR n/N;% (95% CI) Booster at Month 6
Primary strain – 121/163; 74.2 7/75; 9.3 – 1/75; 1.3 0/75; 0.0 – 0/75; 0.0
(66.8, 80.8) (3.8, 18.3) (0.0, 7.2) (0.0, 4.8) (0.0, 4.8)
Booster strain – 144/162; 88.9 4/74; 5.4 – 0/74; 0.0 0/75; 0.0 – 1/75; 1.3
(83.0, 93.3) (1.5, 13.3) (0.0, 4.9) (0.0, 4.8) (0.0, 7.2)
Booster Month 12
Primary strain – – – 141/164; 86.0 7/75; 9.3 5/74; 6.8 – 2/75; 2.7
(79.7, 90.9) (3.8, 18.3) (2.2, 15.1) (0.3, 9.3)
Booster strain – – – 159/164; 97.0 34/75; 45.3 27/74; 36.5 – 27/75; 36.0
(93.0, 99.0) (33.8, 57.3) (25.6, 48.5) (25.2, 47.9)
Booster Month 36
Primary strain – – – – – – 73/74; 98.6 64/75; 85.3
(92.7, 100) (75.3, 92.4)
Booster strain – – – – – – 75/75; 100 72/75; 96.0
(95.2, 100) (88.8, 99.2)
CI, confidence interval; n/N, number of subjects fulfilling definition of outcome/total number of subjects in group; GMT, geometric mean titer; Booster SCR, Booster seroconversion rate defined as percentage of





















the AS03A-H5N1 and the non-adjuvanted H5N1 primary
vaccine groups was nasopharyngitis (n = 8 and n = 10, re-
spectively). After boosting at Month 12, 23.4% (44/188) of
subjects reported at least one unsolicited AE. All MedDRA
preferred terms were reported by no more than three
subjects (1.6%), apart from lymphadenopathy (n = 7) and
axillary pain and nasopharyngitis (n = 4 each). After boost-
ing at Month 36, 21.8% (85/390) of subjects reported at
least one unsolicited AE, which was most commonly
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Figure 5 Injection site (A) and general (B) solicited adverse events during the 7-day post-vaccination period after booster vaccination
























































Time-point (months + days)
Figure 4 Cell-mediated immune responses against the primary vaccine strain (A/Vietnam/1194/2004) after heterologous booster
vaccine at Month 6 and persistence of responses at Month 12 (cell-mediated immunity subset). Data expressed as median values with
first and third quartiles. At Month 6, subjects in the AS03A-H5N1 primary group received one dose of booster vaccine, and subjects in the
non-adjuvanted H5N1 primary group received two doses of booster vaccine.
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Serious adverse events
In subjects boosted at Month 6 in the AS03A-H5N1 pri-
mary vaccine group, from booster to Month 12, 1.1% (3/
265) of subjects reported 5 SAEs, which were ileus, tooth
disorder, tooth impacted, acute tonsillitis, and acute pyelo-
nephritis. In subjects in the non-adjuvanted H5N1 pri-
mary vaccine group who received booster vaccinations,
2.1% (5/236) of subjects reported 6 SAEs from booster to
Month 12, which were colonic polyp, Helicobacter gastri-
tis, clavicle fracture, ligament rupture, and benign ovarian
tumor. In subjects in the adjuvanted H5N1 primary vac-
cine group who did not receive booster vaccination, from
Month 6 to 12, 2.2% (15/672) of subjects reported 22
SAEs. None of these SAEs were considered by the investi-
gator to be related to vaccination.
From Month 12 to Month 12 + 30 days, 0.5% (1/188)
of subjects boosted at Month 12 reported an SAE (facial
bones fracture) and 0.1% (1/645) of non-boosted sub-
jects reported 1 SAE (appendicitis). Between Month 12
and 18, 1.8% (12/645) of non-boosted subjects experi-
enced at least one SAE, of which two were fatal (anoxic
encephalopathy and acute renal failure). None of the
SAEs were considered to be related to vaccination. Be-
tween Months 18 and 30, 3.8% (7/186) of subjects who
were boosted at Month 12 reported 8 SAEs, and 2.5%
(16/645) of subjects not boosted at Month 12 reported
24 SAEs.
In subjects boosted at Month 36, from Month 30 to
42, 3.1% (12/390) of subjects reported 15 SAEs, of which
1 (joint dislocation) resulted in withdrawal from the study.
Among subjects not boosted at Month 36, 2.9% (12/401)
reported 16 SAEs from Month 30 to 42, of which one was
fatal (stab wound). All SAEs in subjects boosted and not
boosted at Month 36 required hospitalization, and none
were considered to be related to vaccination.
From Month 12 to 48, in subjects boosted at Month 6,
12, or 36 in the total vaccinated cohort, 7.1% (14/196),
7.6% (13/170), and 7.6% (28/367) of subjects, respect-
ively, reported at least 1 SAE.
One subject who received primary vaccination but not
booster vaccination experienced a pulmonary embolism
three years after the second dose of primary vaccine.
Blood tests revealed a low Protein S level. The investigator
considered the SAE to be related to the study vaccine; des-
pite the large interval between vaccination and the event,
there was no solid evidence to exclude a causal relation-
ship. The patient recovered upon treatment.
Discussion
This booster study in Asian adults aged 18 to 60 years
showed that one 3.75 μg HA dose of heterologous AS03A-
H5N1 booster vaccine given at Month 6, 12, or 36 after
two primary doses of AS03A-adjuvanted H5N1 primary
vaccine, elicited robust HI antibody responses against both
the booster and primary vaccine strains. Responses to
heterologous booster vaccination given at Month 6 were
markedly lower in subjects who were primed with non-
adjuvanted versus AS03-adjuvanted H5N1 vaccine, despite
receiving two versus one dose(s) of adjuvanted booster
vaccine, respectively. Injection site reactions and solicited
Table 5 Summary of 30-day post-vaccination safety in the total vaccinated cohort
Primary vaccine group
AS03A-H5N1 Non-adjuvanted-H5N1
Month 6 booster N = 265 N = 236
No. subjects with ≥1 unsolicited symptom 65 (24.5%) 54 (22.9%)
No. of events by MedDRA preferred term‡ 88 78
No. of Grade 3 events by MedDRA preferred term‡ 6 6
No. of events by MedDRA preferred term related to vaccination† 26 18
Month 12 booster N = 188 _
No. subjects with ≥1 unsolicited symptom 44 (23.4%) _
No. of events by MedDRA preferred term‡ 67 _
No. of Grade 3 events by MedDRA preferred term‡ 8 _
No. of events by MedDRA preferred term related to vaccination† 25 _
Month 36 booster N = 390 _
No. subjects with ≥1 unsolicited symptom 85 (21.8%) –
No. subjects with Grade 3 unsolicited symptom 9 (2.3%) _
No. subjects with unsolicited symptom related to vaccination† 34 (8.7%) _
†Based on investigators’ assessment of causality; ‡Symptoms reported by participant after a given dose with the same preferred term were counted once; N,
number of subjects in group; Subjects in the AS03-H5N1 primary vaccine group received one booster dose at allocated time-point, and subjects in the non-
adjuvanted H5N1 primary group received two doses of booster vaccine at Month 6; primary vaccine strain, H5N1/A/Vietnam/1194/2004; booster
strain H5N1/A/Indonesia/5/2005.
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general symptoms after each booster dose were consistent
with previous reports of AS03A-H5N1 vaccines, and no
safety concerns were identified over the 48 month follow-
up period.
Highly pathogenic avian-origin H5N1 influenza A viruses
are endemic in domestic birds in many Asian countries,
and since two human cases of H5N1 were reported in
Hong Kong in February 2003, avian-origin influenza A vi-
ruses have continued to spread across Asia, Europe, and
Africa [3]. The majority of H5N1 cases reported in humans
since 2003 have been classified as clade 1 or clade 2, with
multiple clade 2 subclades emerging (e.g. 2.1 to 2.5, of
which 2.1 and 2.3 are further classified as 2.1.1 to 2.1.3 and
2.3.1 to 2.3.4) [3]. The vast majority of the 633 human
cases of avian-origin influenza reported by the WHO be-
tween 2003 and July 2013 [1], were associated with bird to
human transmission, and although H5N1 viruses do not
transmit efficiently between humans, there have been re-
ports of human-to-human transmission in people who
have had sustained, close, and unprotected contact with
infected patients [22]. Indeed, the evolution of H5N1 vi-
ruses capable of human-to-human transmission remains
a threat, and as such, pandemic preparedness is para-
mount. In this study, we provide evidence of robust,
antigen-sparing, cross-clade immune responses following
AS03A-H5N1 pandemic influenza vaccination in a popula-
tion in Taiwan, Thailand, Singapore, and Hong Kong.
In the initial observer-blind study, 21 days after a sec-
ond dose of AS03A-H5N1 influenza vaccine, HI antibody
responses fulfilled the United States Center for Biologics
Evaluation and Research (CBER) licensure criteria for
the vaccine strain (A/Vietnam/1194/2004; clade 1), but
not a drifted strain (A/Indonesia/5/2005; clade 2.1), al-
though substantial HI and neutralizing SCRs against the
drifted strain were observed (50.2% and 91.4%, respect-
ively) [13]. By comparison, the HI antibody responses
after two doses of non-adjuvanted H5N1 vaccine did not
fulfill licensure criteria for immunogenicity against either
the vaccine or drifted strain [13]. These findings support
previous results in a European population of adults, which
showed that AS03A-adjuvantation enhanced immunogen-
icity compared with a non-adjuvanted vaccine, and demon-
strated that two 3.75 μg HA doses of AS03A-H5N1
(Prepandrix™) provided robust vaccine-matched and cross-
clade immune responses [4,5].
Antigen sparing vaccine formulations will maximize the
number of doses available within the existing influenza
vaccine infrastructure, yet this is only part of the challenge
of providing adequate and rapid vaccine coverage in the
event of the emergence and rapid global spread of a highly
pathogenic H5N1 virus. The stockpiling of H5N1 pan-
demic influenza vaccines against clade 1 and clade 2 vi-
ruses to be deployed at the start of a pandemic may
provide cross-protection against the emerging pandemic
strain and prime a population in advance of the manufac-
ture of a vaccine against the emerging strain [6,7]. A previ-
ous study of AS03A-H5N1 vaccines in adults aged 18 to
60 years evaluated various vaccination schedules and
established the feasibility of the prime–boost strategy; sub-
jects received one dose of A/Vietnam/1194/2004 primary
vaccine or two doses given 21 days apart, followed by a
dose of A/Indonesia/5/2005 booster or another dose of A/
Vietnam/1194/2004 vaccine given at 6 or 12 months after
priming. The results showed that two doses of A/Vietnam/
1194/2004 vaccine given 6 months apart provided similar
immune responses against the vaccine strain and higher
cross-clade immune responses compared with two doses
of primary vaccine given 21 days apart [12]. In subjects re-
ceiving one dose of primary vaccine, the heterologous
booster at 12 months elicited robust immune responses
against the primary and booster strains [12].
To further explore the flexibility of the time interval be-
tween priming and booster vaccine, we assessed a two-
dose primary series of AS03A-H5N1 or non-adjuvanted
H5N1 vaccine, followed by one dose of heterologous
AS03A-H5N1 vaccine at Month 6, 12, or 36 in subjects in
the AS03A-H5N1 primary vaccine group, or two doses of
booster vaccine at Month 6 in the non-adjuvanted H5N1
primary group. In subjects who were primed with the
non-adjuvanted vaccine, two doses of the adjuvanted
heterologous booster vaccine elicited strong HI antibody
responses against the primary and booster strain which
fulfilled CBER licensure criteria after the second but not
the first booster dose. In subjects who received AS03A-
H5N1 primary vaccine, only one dose of booster at Month
6 months was needed to elicit booster responses that ful-
filled CBER licensure criteria. Neutralizing antibody re-
sponses in the AS03A-H5N1 primary group supported the
HI results, with a neutralizing booster SCR of 90.2%
against the booster strain 21 days after the Month 6
booster dose.
Of note, HI antibody SCRs, SPRs, and GMTs after two
doses of booster vaccine at Month 6 were lower in the
non-adjuvanted H5N1 primary group compared with one
dose of booster vaccine in the AS03A-H5N1 primary group.
This phenomenon has been previously reported in a Phase
II study which showed that HI antibody responses where
markedly higher in subjects primed with AS03A-H5N1 vac-
cine compared with those primed with non-adjuvanted
H5N1 vaccine [23]. Moreover, the Phase II study showed
that HI antibody responses after AS03A-H5N1 booster vac-
cine were stronger in un-primed subjects compared with
subjects who had received non-adjuvanted H5N1 priming
vaccine, which not only highlights the role of the adjuvant
for enhancing the development of immune memory, but
also suggests that non-adjuvanted vaccine may have a nega-
tive effect on priming [23]. Consistent with this hypothesis
are the findings from a study conducted during the 2009
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swine-origin H1N1 influenza pandemic, which showed that
HI antibody responses to AS03A-H1N1 vaccine were lower
in subjects who had received a non-adjuvanted seasonal in-
fluenza vaccine during the preceding two seasons com-
pared with those who had not [24]. The apparent negative
effect of previous non-adjuvanted seasonal influenza vac-
cination on responses to AS03A-H1N1 vaccination did not
appear to be associated with HI antibody levels at baseline,
and the cause of this phenomenon remains to be estab-
lished [24].
This study also demonstrated the feasibility of a highly
flexible booster schedule, with strong cross-clade anam-
nestic responses observed with the booster dose given at
Month 6, 12, or 36 post-priming. HI antibody responses
fulfilled CBER licensure criteria against the primary and
booster strain after booster vaccination at Month 6, 12,
and 36, and GMTs after booster vaccination appeared
higher than those observed after primary vaccination,
suggesting strong immune memory recall. Priming with
AS03A-adjuvanted pre-pandemic vaccine induced im-
mune memory, which will allow for low-dose, rapid
cross-protection with boosting at various time-points,
offering highly flexible heterologous prime–boost sched-
ules that can be adapted according to global need, pan-
demic strain evolution, vaccine circulation, and logistical
implications in the event of a H5N1 pandemic outbreak.
This should help mitigate transmission and reduce the se-
verity of disease during the different phases of a pandemic.
To evaluate the level of protection offered after priming
and boosting, we assessed immune persistence at various
time-points up to 48 months post-primary vaccination. At
Month 48, HI SPRs against the booster strain were 39.2%,
61.2%, and 95.6% in subjects boosted at Month 6, 12, or 36
post-priming, respectively. Although immune responses
decreased with time, this result suggests that vaccinated
populations could be potentially protected for up to three
years after primary or booster vaccination, which is likely
to far exceed the peak of the pandemic.
The induction of T and B cells is an important compo-
nent of the immune response, and CD4+ effector and
memory T cells have various protective roles in the innate
response to influenza infection [25]. AS03A-adjuvanted
H5N1 pandemic influenza vaccine has been previously
shown to elicit strong T-cell and B-cell responses in adults,
which indicates immune memory and antibody persistence,
arising from both quantitative and qualitative changes in T-
cell responses [26]. In our study, we evaluated CMI based
on Th1-specific activation marker expression after in vitro
re-stimulation of influenza-specific CD4+ and CD8+ T-
cells. There were no CD8+ responses, but antigen-specific
CD4+ responses were observed, expressing CD40L, IFN-γ,
IL-2, and/or TNF-α, after primary and booster vaccination.
CMI responses at after boosting at Month 6 appeared
markedly higher in those primed with AS03A-adjuvanted
vaccine than in those who received non-adjuvanted vaccine,
supporting previous reports suggesting that adjuvantation
has a positive priming effect on CD4+ T-cell responses.
The reactogenicity profile after booster vaccination
was consistent with that observed during the primary
vaccination study [13]. The most frequent injection site
event was pain, and Grade 3 pain was uncommon, as were
other local events such as redness, swelling, and ecchym-
osis. After booster vaccinations the most frequent general
solicited events were myalgia, headache, and fatigue. The
frequency of solicited symptoms observed after booster
vaccination was consistent with that observed during the
primary vaccination study [13]. During the 30-day period
after booster vaccinations, ≤24.5% of subjects reported at
least one unsolicited AE, and the rate of Grade 3 unsoli-
cited AEs was low (≤2.8%). No safety concerns were iden-
tified, and the safety profile of the AS03A-H5N1 booster
vaccine appeared acceptable.
Conclusion
In conclusion, priming with two doses of AS03A-adjuvanted
H5N1 pandemic influenza vaccine provides robust and
durable, cross-clade immunogenicity. Strong cross-clade
anamnestic responses were observed after one dose of
AS03A-H5N1 heterologous booster vaccine given up to
36 months after priming, supporting the feasibility of highly
flexible prime–boost schedules with AS03A-adjuvanted
H5N1 vaccines. No safety concerns were raised during the
48 month extension study period.
Prepandrix is a trademark of the GlaxoSmithKline
group of companies.
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Additional file 1: Cell-mediated immune responses against the
booster vaccine strain (A/Indonesia/5/2005) primary vaccine strain
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